Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an update.
Neuren reported that FDA written feedback validated its planned IND-opening study for NNZ-2591 in hypoxic ischemic encephalopathy, contingent on additional juvenile animal data before a late-2026 start, while guidance for Pitt Hopkins syndrome confirmed an acceptable endpoint strategy that now requires refined trial design for an initiation target in 2026. The company emphasized it can fund both programs with minimal financial impact, is progressing the Koala Phase 3 trial in Phelan-McDermid syndrome, and sees the regulatory clarity as reinforcing its rare-disease pipeline momentum.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$19.50 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals, an Australian drug developer, focuses on neurological disorders emerging in early childhood and markets the FDA-approved Rett syndrome therapy DAYBUE while advancing NNZ-2591 for multiple rare neurodevelopmental conditions with orphan-drug incentives.
Average Trading Volume: 340,914
Technical Sentiment Signal: Hold
Current Market Cap: A$2.11B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.